Liu, Kuan TingKuan TingLiuQuiñones, Edgar DanielEdgar DanielQuiñonesLiu, Ming HsinMing HsinLiuLin, Che WeiChe WeiLinChen, Yan TingYan TingChenChiang, Chia CheChia CheChiangKEVIN CHIA-WEN WUFan, Yu JuiYu JuiFanChuang, Er YuanEr YuanChuangJIASHING YU2023-07-042023-07-042023-01-0121922640https://scholars.lib.ntu.edu.tw/handle/123456789/633366Thrombolytic and antithrombotic therapies are limited by short circulation time and the risk of off-target hemorrhage. Integrating a thrombus-homing strategy with photothermal therapy are proposed to address these limitations. Using glycol chitosan, polypyrrole, iron oxide and heparin, biomimicking GCPIH nanoparticles are developed for targeted thrombus delivery and thrombolysis. The nanoassembly achieves precise delivery of polypyrrole, exhibiting biocompatibility, selective accumulation at multiple thrombus sites, and enhanced thrombolysis through photothermal activation. To simulate targeted thrombolysis, a microfluidic model predicting thrombolysis dynamics in realistic pathological scenarios is designed. Human blood assessments validate the precise homing of GCPIH nanoparticles to activated thrombus microenvironments. Efficient near-infrared phototherapeutic effects are demonstrated at thrombus lesions under physiological flow conditions ex vivo. The combined investigations provide compelling evidence supporting the potential of GCPIH nanoparticles for effective thrombus therapy. The microfluidic model also offers a platform for advanced thrombolytic nanomedicine development.enanimal use alternatives (3Rs) | nanoparticles | photothermal thrombolytics | thrombosis therapy | thrombosis vessels-on-a-chip[SDGs]SDG3journal article10.1002/adhm.202300682372895402-s2.0-85161651134https://api.elsevier.com/content/abstract/scopus_id/85161651134